|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 968 USD | -1.05% |
|
-0.00% | +10.21% |
May 2 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals Inc missed Wall Street estimates for first-quarter profit on Thursday due to softer sales of its blockbuster eye drug Eylea and its eczema treatment, Dupixent.
Excluding items, the company reported a profit of $9.55 per share for the quarter, compared with analysts' estimates of $10.09 per share, according to LSEG data. (Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 968 USD | -1.05% | -0.00% | 104B | ||
| 90.24 EUR | -0.35% | -3.16% | 123B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +10.21% | 104B | |
| +8.29% | 114B | |
| +0.41% | 22.28B | |
| -11.90% | 22.41B | |
| -5.99% | 19.07B | |
| -37.36% | 18B | |
| -5.17% | 17.89B | |
| +7.70% | 14.28B | |
| +37.65% | 12.55B | |
| +271.25% | 7.62B |
REGENERON PHARMACEUTICALS, INC. 
